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DR. FOX: I would like to ask Dr. Paterson in relation to his last slide whether
the antigen to which he had reference was a bacterial antigen or whether it was a
tissue specific antigen.
DR. PHILIP PATERSON: What I want to stress is that there need be no bac-
terial antigen-host cell conjugate or postulated altered antigenic composition of the
host cell as a result of infection. Because of intimate association with the living host
cell, cell damage occurs when the antigen interacts with whatever immune response
is made by the host. The bacterial antigens can be of any kind-polysaccharides, lipo-
polysaccharides, or proteins.
DR. L. THOMAS: Do you have tentative answers from your transfer experiments?
I gathered from your last remarks that you have transferred lymphocytes and found
beta-glucuronidase in the recipients. Did you also get lesions?
Also did you transfer "staph-sensitive" lymphocytes to normal rats and get a re-
action, or must the rats be "staph-prepared?" This line might tell you, if it hasn't
already, whether the immunologic reaction is directed against staphylococcal antigens
or against host cell antigens. A very important part of the issue at this stage is wheth-
er lesions appear following transfer.
Finally, have you tried transferring lymphocytes by subcapsulary implantation to
see if these cells replicate and lesions ensue?
DR. PHILIP PATERSON: First, the animals that have been involved in the
transfers have been examined histologically and have peritubular inflammatory changes
that accompany the enzyme urine excretion.
Second, we have transferred "stap-sensitive" lymphocytes into normal rats and ob-
served neither enzyme outpouring nor cellular inflammation.
Third, we did not use Elkin's technique of injecting "staph-sensitive" lymphocytes or
normal lymphocytes subcapsularily into either normal or staphylococcal infected kid-
neys of rats.
DR. FARR: I am sure that Drs. Thomas and Paterson would both agree that the
transfer of a disease process by cells rather than by serum can no longer be accepted
as evidence that the disease process in question is necessarily mediated by a tuberculin-
type of cellular hypersensitivity. A fine case in point is the nephritis produced in sheep
following immunization with basement membranes from other sheep. Early efforts to
produce nephritis in normal sheep by the transfer of serum failed, and it was thought
for a time that the process was mediated by cellular type of immune reaction. How-
ever, it is now known that the disease can be transferred to normal sheep by serum
from nephritic sheep if the proper population of antibodies are obtained by removing
the kidneys of the nephritic donor several days before the serum transfer.
Regarding the very appealing idea that Dr. Paterson has been discussing, I would
suggest that we shouldn't adopt the "one bug-one disease" notion. The hallmark of
the true allergic state is that many are called but few are chosen. Dr. Paterson brought
this out in his presentation where many of his rats apparently produced a one-shot
defect and then became well again. If this mechanism is to be called upon in chronic
bronchitis or emphysema in the human, we should be looking for unusual immune
reactions that are mounted by individual people to individual organisms, maybe even
individual strains of organisms. Just as only a few of the many people with an immune
response to ragweed pollen have hayfever, I would expect that only a few of many
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people with immune responses to a given organism would have an untoward physiologic
event as a result of the immune response in question.
DR. KLEINERMAN: I noticed that the fifth item on Dr. Paterson's analogy list
indicates there to be an ill-defined histologic picture in emphysema. I dare say the im-
munologic picture to me as a pathologist would be more ill-defined than the histologic
picture is to him. But if a group of pathologists were looking at the end result of the
emphysema picture histologically, I do not think that they would disagree or that
they would consider it to be ill-defined.
Secondly, Dr. Loosli indicated that the theories of McLean concerning scarring
and organic obstruction in and about bronchioles were considered to be an intimate
part of the picture. I think that there have been many studies to date, including those
of Gough and others, which indicate there is little or no organic obstruction in the
terminal bronchioles or in any of the conducting passageways in this disease.
DR. PHILIP PATERSON: I observed disagreement yesterday about the his-
tological end point of emphysema and whether we are talking about overdistension or
destruction. This kind of discussion has been going on for years. The main point, how-
ever, is that the histological end point does not permit conclusions about the etiological
mechanism. If one shuts off the blood supply to the kidney, morphologically one ob-
serves the same response that is seen upon deliberate infection of the kidney. Straw-
bridge produces something he calls emphysema in the rabbit by vascular occlusion.
Reid produces what he calls emphysema by exposing animals to sulfur dioxide. In
terms of its etiological implications, the lesion is not crisply defined.
DR. BOREN: I think Dr. Lepper has a very important point in regard to sequence
exposures. I would like to report two observations on sequence exposures of carbon
and NO2. If animals inhale carbon first and then NO2, we observe destruction in lungs,
whereas if we reverse this sequence, destruction is not seen. Furthermore, in the first
experiment in which carbon was given first and then NOs, the manner in which we
gave NO2 was the determining factor. Surprisingly enough, it was neither a high
concentration nor a low concentration which gave the greatest effect. Cycles of low
exposures for three weeks and then a single high exposure gave the most effect. By
the use of sequence exposures we can more precisely determine timing and concentra-
tions of what we are doing.
DR. KILBURN: Dr. Paterson brings to mind a pet subject of mine. Nobody seems
to look at sputum any more; everybody looks at blood and urine. I wonder if anyone
here has looked in sputum for any biochemical derivative of lung cells which might
indicate the intensity of destruction of lung cells. One would have to be quite careful
that this were done in the absence of a tremendous polymorphonuclear purulent sputum,
but we have numerous patients who produce lots of sputum that is low in "polys."
Does anyone in the room have any idea about beta-glucuronidases in sputum?
DR. PHILIP PATERSON: The transtracheal or laryngeal puncture method of
obtaining respiratory secretions from chronic lung patients with acute exacerbations
is a vital step in obtaining sound interpretable bacteriologic or virologic data, and
is far superior to sputum as ordinarily supplied. There is beta-glucuronidase in these
secretions, but whether it is derived from lung parenchymal cells or inflammatory
cells cannot be determined at present. We are looking for lung-specific antigenic con-
stituents in these secretions. What we want to know is whether, in those people who
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have secretions without any bacteria and who have no evidence of virus infection, we
can demonstrate lung hypersensitivity. Can we demonstrate antigen which causes
lymphocyte transformation in these patients?
DR. KARZON: I would like to comment on the use of the enzyme beta-glucuroni-
dase as an indicator of cell injury. It has been proposed by Allison and colleagues
that injury of cells by virus is mediated by the acid hydrolases which are released by
alteration of lysosomal membranes. Beta-glucuronidase is one of the enzymes normally
contained in lysosomes which, under the stimulus of virus infection, may be released
into the cytoplasm. This then results in the cytopathic effect with which we are
familiar. To support this concept, Allison has shown that the lysosomes become
"leaky," with release of enzymes into the cytoplasm, somewhat before one can see
cytopathic effect using light microscopy. Studies in our laboratory, while supporting
this general thesis, indicate that the relationships may be more complicated. Signifi-
cant viral effects can take place in the cell, e.g., giant cell formation or gross alteration
of the cell membrane, with very little effect that one can measure in lysosomal enzyme
content or distribution in cells. On the other hand, it should be recognized that many
kinds of injury seem to be quite capable of altering the permeability of lysosomal mem-
branes. Thus, the specificity of the virus action is not clear. Beta-glucuronidase in fact
may have little to do, as a specific enzyme, with cellular destruction by viruses. It is
generally used as an indicator of lysosomal permeability because it is easy to measure.
DR. LEPPER: We had some experience with trying to do somewhat similar
things with sputum. We collected 24-hour sputum specimens, dialyzed off the mineral
content and used the weight of lyophilized nondialyzable solids as a reference to give
ratios of substance, such as sialic acid and DNA content per unit. We used DNA as
an index of white cell destruction, primarily in the sputum. In addition we measured
total protein, sialic acid and other sugars, as well as some enzymes. One of our prob-
lems, of course, was to know how much of the material is from saliva. We tried to
control this by using the amylase sialic acid content of pure saliva from the same
patients as a correction factor. This was done in a group of chronic bronchitics who
were on a controlled trial. Patients from each of the drug groups, including the
placebo, were selected. The upshot was a mish-mash-we never published it because
the ratios bounced all over.
We then tried to get away from the salivary problem by taking aspirates from
tracheatomized patients. This was not much better. It is very hard to get the proper
base against which to do these things. Some of the enzymes, of course, have tremendous
activity per molecule, hence minor errors are magnified. The kinds of things we meas-
ured just were not very helpful.
DR. HARFORD: Dr. Loosli mentioned work we have done concerning mechanisms
by which influenza viral infection of the mouse lung lowers resistance to superimposed
pneumococcal pneumonia. In these experiments, we were impressed by the fact that
pulmonary edema may furnish a culture medium in which inhaled bacteria may grow
and produce pneumonia. As a clinician, I have also been impressed by the large
amount of mucus secretions of many patients with chronic lung disease and have
speculated that susceptibility of such patients to bacterial infection is the result of
bacterial growth in these secretions. In support of this idea is the considerable body
of information indicating that the pathogenicity of many bacteria for experimental
animals is greatly enhancedby suspending the inoculumin mucin.
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DR. H. V. THOMAS: In response to Dr. Kilburn's question, I would like to add
that we have observed an elevated level of histamine or histamine-like substance in the
sputum of allergic rhinitis and asthma patients visiting the Kaiser Allergy Clinic
for the first time with respiratory discomfort. The consistently higher levels of sputum
histamine among these patients than in individuals without respiratory distress suggest
a relationship between this amine and respiratory discomfort.
DR. HAYDON: Based on our previous impression that rabbits developed a toler-
ance to NO2 in repeated exposures, we recently found that rats develop a similar
tolerance. Lavage fluid from the bronchi of experimental rats contained an electro-
phoretic peak not found in serum. Perhaps the material in this peak is related to the
tolerance.
DR. FABRICANT: I just would like to add one point. In the rat model, myco-
plasmal infection does not get down into the lung unless one of two situations occurs.
Either experimentally by temporary bronchial ligation causing the organisms to in-
vade, or, as a secondary response to a viral infection otherwise, mycoplasmae will stay
in the upper respiratory tract.
DR. MIDDLETON: Nobody has spoken much about surfacant which, as I under-
stand it, is now identified as diethylmethyl dipalmitoyl-lecithin. Lecithin is the pre-
cursor of lysolecithin which for years has been known to be a very potent hemolysin.
More recently it has been demonstrated to produce a very wet inflammatory reaction
when given subcutaneously to mice. It produces wheal and erythema reactions in the
skin of man, and releases histamine from leukocytes. All of these reactions occur in
response to very low concentration of lysolecithin. In thinking about a final common
pathway of injury in destructive pulmonary emphysema, I wonder if this profoundly
.cytolytic substance might be of pathogenetic importance.
DR. VORWALD: It seems to me that we have gathered here to debate the mecha-
nisms in the production of chronic bronchitis and obstructive emphysema as seen in
human subjects. It is evident that this disease develops only after a long period of
time, perhaps related to age of tissue, not only anatomical age but also functional age.
We must recognize that human subjects are exposed to a multitude of respiratory
challenges during their lifetime. The interaction between these various challenges
must be identified.
It seems appropriate to ask whether anyone can present evidence of synergism or
antagonism relative to substances which one inhales at low level, in trace amounts
either concurrently or sequentially, whereby one substance will influence the pul-
monary deposition and biologic activity of another substance, especially in the causa-
tion of chronic pulmonary disease, whether it be chronic bronchitis or emphysema?
DR. CARRINGTON: I would like to come back to the problem of the end point
which must be considered if we are going to discuss model systems. Dr. Kleinerman
has tried to clarify this; and with all due respect to Dr. Paterson, I think he has
introduced a doubt which need not be considered any longer.
It is true that many years ago pathologists were unable to define or describe em-
physema with any degree of satisfaction to their coworkers, but this is now an ob-
solete issue. There are debates on pathogenesis and etiology of the lesion; if there
were not we wouldn't have a conference like this. There is a debate as to whether, under
the term emphysema, we should include simple dilatation or only those lesions which
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have destruction. Dr. Pratt described this controversy and has presented his own
stand. Fine points of semantics is a problem. For example, a lesion which most of us
would call centrilobular emphysema, Dr. Lynne Reid prefers to call panlobular but
localized. However, there is no real problem now in recognizing the end point. Today
we have good techniques available for identifying emphysematous lesions and de-
scribing them adequately. All pathologists using a good preparation can agree on
what is seen in any given case, whether it is a spontaneous human or experimental
lesion. We will have a great deal of debate, however, in interpreting an experiment if
the preparations are poor.
Since we have achieved techniques and descriptive methods with which we can
agree not only on what is in the lung but, to a fair degree, on quantitative terms as
well, we should no longer set up any experimental model designed to produce em-
physema and ignore pathological interpretation. All too many experiments have been
greatly weakened by the fact that good anatomical preparations, using the techniques
developed over the last two decades, have been ignored in the experimental plans. We
can no longer use the justification that "pathologists are still arguing about this" to
leave out a good description of good preparations of the end point in an experiment
aimed at producing emphysema.
DR. FABRICANT: Since I brought up the subject of the recognition of minimal
and early cases of emphysema in the younger individual, I would like to ask Dr.
Kleinerman whether he still feels that the bronchiolitis and similar lesions are also
not present in these early stages. Might not that be a factor in pathogenesis, but be
absent in the late stage of the disease?
DR. KLEINERMAN: Most certainly they could be present. As a matter of fact,
I personally believe that they are. My point is that there is no organic obstructive
element. One should not infer that inflammation or bronchiolitis could not be or is not
present.
DR. KILBURN: I think in talking about aging in the lung, one has to be careful
to differentiate between populations of cells which turn over at rather rapid rates, and
presumably, unless their genetic information is altered, do not age, and cells which
are not renewed and essentially remain in situ once they are laid down. The lung has
both of these. Part of its uniqueness lies in the fact that the latticework is composed
of nonrenewing cells. Much of what we are discussing, I think, concerns renewing cells.
Thus, it is difficult to interpret what Dr. Vorwald means when he talks of aging or
what many other people have discussed today when they talk about damage.
There must be several types of alterations. One is death of cells. Another is altera-
tion of the genetic information of the cells so that, unlike normal cells, they produce
more airway epithelial cells, more alveolar lining cells or more alveolar macrophages.
DR. VAN ARSDEL: Since enzymes have been brought up several times as well
as genetic influences and the matter of aging and the early development of emphysema,
I wonder if this isn't an appropriate time for someone to comment on human familial
alpha-1-antitrypsin deficiency and its unexplained association with emphysema of
relatively early onset in almost 100 per cent of persons with the deficiency. If this
could be reproduced in animals, one might be able to produce experimental emphysema
by measures which would otherwise be ineffective. Study of such a model might also
explain the association between this enzyme defect and emphysema in man.
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DR. LOOSLI: I had not planned to comment on the association between the en-
zyme defect and emphysema. I would like to say that influenza PR8 virus pneumonia
can be produced in mice by injecting large amounts of virus intraperitoneally. By this
route of administration there is little or no involvement of the bronchial walls or
epithelium. However, following the intratracheal route of virus administration, both
the bronchial and peripheral lung tissue show inflammatory reactions. This is prob-
ably the situation in influenzal infections in man.
DR. HARFORD: I was interested in Dr. Kleinerman's remarks about lack of
obstruction. Did I understand that in chronic obstructive respiratory disease, there
isn't any obstruction?
DR. KLEINERMAN: You hit the heart of the problem. As a matter of fact, there
is no visible organic obstruction in cases of emphysema and in cases of severe chronic
bronchitis anatomically defined. Thickening of the mucous membranes and hypertrophy
of the glandular elements are found in chronic bronchitis. But again the lumens, except
for mucus secretion, are usually patent.
Now, with regard to the question that Dr. Van Arsdel asked. I raised the question
of emphysema in the young, and I feel constrained to tell you that I do not have the
clinical information as yet on the cases which we studied. We are studying them
blind first, attempting to define the lesions without clinical insight. We will go back
later-if we find enough to warrant it and if it is worthy of further study-and try
to find out if these people had any peculiarities, clinically or by history.
DR. VORWALD: In answer to the questions about the enzymatic pattern of the
lung, for the past number of years-seven or eight years to be exact-we have been
studying the enzymatic pattern of the lungs of rats living in clean air or living in
dirty air as drawn off the streets in Detroit. We have not found any significant change
in the enzymatic pattern of the lung between the two experimental groups.
DR. ABINANTI: Relative to scarring and aging, I would like to comment on an-
other factor, which is aging of cells. It is conceivable that emphysema is a disease
which is the end product of an impaired physiologic state of the cells. Illustrative of
such a possibility are the implications of recent findings on scrapie, a chronic neurologic
disease of sheep of presumed microbial origin. A group of British investigators has
demonstrated inactivation of the scrapie agent following treatment of cytoplasmic
membranes with dilute solutions of urea. They postulate that the scrapie agent alters
the normal ion exchange function of the cell membrane resulting in degenerative
changes within the cell. Any factor or factors which would alter the normal physio-
logic functioning of the lung at the cellular level could be instrumental in producing a
disease such as emphysema.
DR. TYLER: We have been studying the distribution of enzymes using histo-
chemical procedures which are not quantitative, but which localize enzyme activity.
In the horse, we see differences in the distribution of a hydrolytic enzyme between
areas of the same lung which have enlarged air spaces and in areas which have normal
sized air spaces.
DR. KARZON: Further consideration should be given to virus infections as a
possible mechanism of repeated or continuing insult in chronic progressive lung
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disease. The fact that delayed hypersensitivity has been shown to develop following
certain viral infections makes this concept a reasonable one for consideration. Some
of the ensuing remarks are hypothetical, but may nevertheless be relevant at a con-
ference such as this. Hypersensitivity under certain circumstances does appear to
participate in recovery from virus infection as observed by Kempe and ourselves, and
may even participate in the genesis of the pathology itself, as noted by Hotchin. The
hypersensitive state may persist for years, and in exceptional cases such individuals
may react adversely to subsequent challenge. Certain lesions in the central nervous
system may be late manifestations of immunological reactions, originating with viral
infection, although at present we are not aware of analogous manifestations in the lung.
The relationships of virus infection and autoimmune disease should be considered.
The limiting envelope of many viruses appears to be derived from host cell membrane.
In the case of influenza, and possibly in other enveloped viruses, host antigen is in
this manner incorporated into the virion. Is it not conceivable that repeated infections
with respiratory viruses (such as myxoviruses) may offer repeated immunological
insults through the common pathway of altered host lung antigen incorporated in the
viral envelope?
Recently, the introduction of new viral antigens as vaccines has refocused attention
upon the possible role of viral hypersensitivity as a pathogenetic mechanism. Children
who received multiple doses of inactivated measles vaccine in alum adjuvant often
develop unusual reactions when given live attenuated measles vaccine or exposed to
natural measles. In children receiving inactivated measles vaccine, subsequent ex-
posure to measles has resulted in an exaggerated but atypical infection with vesicular,
petechial or hemorrhagic rash, and marked pneumonitis; some workers have shown
live vaccine administration to be attended by unexpected local inflammatory response.
Enhanced reactivity has been reported in other viral systems following sensitization
with inactivated virus. For example, McNeill reported in 1966 and Ehrengut in 1959
that the administration of inactivated vaccinia in animals and human subjects may
exaggerate local response upon revaccination with live virus. It was reported at a
recent conference that subjects immunized with inactivated respiratory syncytial virus
or Mycoplasma pneumonia developed an unusually severe pneumonitis on exposure to
the agent.
Our group in Buffalo has attempted to study the mechanism of the unusual reactions
following immunization with inactivated measles virus. It has been shown that children
receiving inactivated measles vaccine regularly develop delayed dermal hypersensitivity
to live measles vaccine. The initial data indicate probable sensitivity to both viral
and tissue culture components, although the relationship of these findings to the ob-
served clinical reactions remains to be clarified. One approach under current investi-
gation is to determine the content of human blood group A and B antigens in viral
vaccine products prepared from cell cultures containing natural A and B substance.
The latter serve as sensitive markers for the presence of host tissue antigen as a con-
taminant or possibly incorporated into the virion. For the reason stated, and until
more information becomes available, concern should be expressed regarding the wide-
spread use of inactivated viral vaccines prepared in alum adjuvant.
A second point, and perhaps one which is not unrelated to the problem of local hy-
persensitivity to viruses or other microorganisms, is the problem of the distribution of
immunoglobulins in the circulation and in body secretions. It is now evident that
secretory antibody has as its major component a unique class of IgA immunoglobulins
originating from IgA-rich immunocompetent cells lining the respiratory and intestinal
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walls. Live virus infections, i.e. oral poliovirus vaccine (our laboratory) or nasal
parainfluenza infection (Smith, Purcell Bellanti and Chanock) have been shown to
produce secretory IgA antibody, while their inactivated counterparts introduced
parenterally do not. Studies directed at salivary or bronchial IgA immunoglobulin are
suggested as tools for the detection of local antigen-antibody reactions involving tissue
components or microorganisms.
DR. MYRVIK: I think the term "delayed hypersensitivity" is a misleading term
in some respects. For example, if rabbits are sensitized intravenously with small
amounts of killed tubercle bacilli and challenged three to four weeks later, a profound
macrophage response occurs in the lung. This is an accelerated hypersensitivity-like
response. However, most of these rabbits are tuberculin negative.
On the other hiand, if tubercle bacilli are injected in the skin, rabbits become tuber-
culin positive but fail to exhibit an accelerated macrophage response to intravenous
challenge. The pulmonary macrophage response seems to be distinct in that it lacks
the inflammatory component which is characteristic of the classical tuberculin reaction.
In addition, if a tuberculin positive animal is challenged intratracheally or intravenous-
ly with tuberculin, marked inflammatory lesions develop in the lung. In terms of timing
and the cellular nature, these reactions are delayed hypersensitivity responses. How-
ever, they qualitatively differ.
DR. FOX: In the presentation that I made yesterday I rather carefully refrained
from raising the question of hypersensitivity to respiratory tissue antigens on the
grounds that these tissues are not well separated from the immunologic apparatus of
the body; hence, even though tissue antigens might be incorporated in the envelopes
of viruses such as the myxoviruses, they might not be expected to invoke immunologic
response. In other words, the mechanism of tissue specific antigen invoking autoim-
mune responses is not difficult to conceive of in the case of the central nervous system.
My question is whether one can carry the same concept over to a tissue like the
respiratory tissue, the antigen' of which is either in the viral envelope or in the tissue
from which it is released by cytolytic effects of the virus.
DR. FARR: In recent years, my personal feeling is that the way tolerance gets
terminated is probably similar to the haptene conjugate studies during which just
enough conjugates are put on a native protein to make it far enough from self to be
recognized as foreign, yet remaining near enough to self to evoke an antibody response
to one's own tissue. In this connection, I would refer you to Dr. Weigle's experiments
on thyroglobulin in which he prepares arsanil-sulfanil rabbit thyroglobulin; intra-
venous injections of this material have capacity to terminate tolerance to native thyro-
globulin in the rabbit. He can then inject native rabbit thyroglobulin and evokes an
anamnestic anti-native thyroglobulin response. However, several injections of native
thyroglobulin gradually convert the rabbit back into the normal state of tolerance to
native thyroglobulin.
Now, how might this mechanism apply to a lung? Lung tissue would have to be
conjugated, or somehow changed by enzymes, viruses or one of the inflammatory
products, if natural tolerance is going to be terminated and autoantibodies against
lung are to be produced. It is also possible that some infectious agent such as a virus,
as it occurs in its natural state, might present antigenic groups which by themselves
are far enough from host-self to be recognized as foreign, yet near enough to antigens
in the lung to evoke an autoantibody response tolung tissue.
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There is one other quick point I would like to make regarding the initiation of
antibody production. Quite separate from how much antibody is produced, the initiation
of antibody production that follows mass action law and the concentration of antigen
to which the antibody producing mechanism is exposed is far more important than
the total body burden of antigen. By that I mean, a trace amount of antigen in a small
nudus will initiate antibody synthesis much more efficiently than the same dose of
antigen distributed throughout the plasma-protein body compartment. It seems to me
that if a trace constituent of plasma or tissue were to become concentrated for one
reason or another on the surface of a bacterium or a virus, this situation could initiate
antibody synthesis to that trace constituent. Under these circumstances, the immune
mechanism would have been tolerant to the low concentration of plasma or tissue
constituent but not to the high concentration created on the cell surface. I don't know
of any evidence that this actually occurs in autoimmunity but it is something to con-
sider. For example, I think this concentration phenomenon explains why injections of
depot penicillin initiates allergies to penicillin much more frequently than orally ad-
ministered penicillin.
DR. MUFSON: At this point in a conference on the development of animal model
systems for the study of etiology of emphysema, perhaps the term "animal model sys-
tem" should be examined. Significantly, the conference title implies that not one
system, but two or more systems must be developed. Almost certainly, a multifactorial
etiologic system will prove to be the basis of human bronchitis and emphysema. Nat-
urally occurring chronic respiratory disease of animals, small or large, does not appear
to provide satisfactory models. A satisfactory animal model might be a small or
medium-sized animal, economical to house, and reasonably easy to handle, free of
naturally occurring respiratory disease, and, most important, in which a disease
identical to or very similar to human bronchitis or emphysema can be produced and
thus allow for short-term and long-term investigations of one or more factors sus-
pected of playing a role in the human disease.
DR. ABINANTI: While no one would argue with Dr. Mufson's statements rela-
tive to producing disease in animals with human pathogens, such a limited definition
if adopted, would seriously hamper research. In the case of emphysema and other
chronic and degenerative diseases, establishing the etiologic base would appear hope-
less unless it is possible to reconstruct the series of events occurring during the pre-
vious 10 to 30 years. It is difficult for me to appreciate that man does not exist in
some unity with other animal species and a certain degree of relevance does not exist
between findings in animals and man. The presentation of Dr. Gareth Green at this
symposium is an example of creating from animal model systems a profile of persons
who might develop emphysema.
DR. WEISER: I really don't think that we should leave this conference without
presenting another thought about antigens, the breaking of tolerance and autoimmune
disease, because there is another concept. Namely, there are many antigens in the
body that are occult, that do not reach antibody-forming tissue. We are not, indeed,
tolerant of them. A great many people have subscribed to this concept, and I believe
that Freund would turn over in his grave if he thought we were to neglect it. Cer-
tainly one can inject brain into animals and get CNS disease without Freund's ad-
juvant. Moreover, I am not sure that Freund's adjuvant acts as Dr. Farr has indicated.
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